H.C. Wainwright resumed coverage on RAPT Therapeutics with a new price target
$RAPT
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright resumed coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $6.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2025 | $6.00 | Buy | H.C. Wainwright |
| 12/26/2024 | $10.00 | Neutral → Buy | H.C. Wainwright |
| 11/13/2024 | $7.00 → $2.00 | Buy → Hold | Stifel |
| 11/11/2024 | $8.00 → $2.00 | Overweight → Neutral | Piper Sandler |
| 11/11/2024 | Neutral → Underweight | JP Morgan | |
| 5/14/2024 | Outperform → Peer Perform | Wolfe Research | |
| 5/10/2024 | Buy → Neutral | Guggenheim | |
| 5/10/2024 | $13.00 → $4.00 | Overweight → Equal Weight | Barclays |
H.C. Wainwright resumed coverage of RAPT Therapeutics with a rating of Buy and set a new price target of $6.00
H.C. Wainwright upgraded RAPT Therapeutics from Neutral to Buy and set a new price target of $10.00
Stifel downgraded RAPT Therapeutics from Buy to Hold and set a new price target of $2.00 from $7.00 previously
- RAPT obtains worldwide rights excluding China - - Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales - - Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China - - RAPT plans to initiate Phase 2b trial in food allergy next year - - RAPT to host a conference call at 8:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patient
- RAPT to host a conference call today at 8:30 am ET - SOUTH SAN FRANCISCO, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced that the U.S. Food and Drug Administration (FDA) has verbally notified the company that a clinical hold has been placed on the company's Phase 2b trial of zelnecirnon (RPT193) in atopic dermatitis and its Phase 2a trial in asthma. The company expects to receive a formal clinical hold letter from
- Confirmed objective response rate (ORR) of 40% in PD-L1 positive (TPS ≥1%) patients with no prior checkpoint inhibitor therapy (CPI) - Median progression-free survival (PFS) of 6.3 months in PD-L1 positive patients at time of data cut off - Confirmed ORR of 50% in patients with PD-L1 high expression (TPS ≥50%) and 38% in patients with PD-L1 low expression (TPS 1-49%) - RAPT to host webcast conference call today at 10:00 am PT SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with s
4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)
4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)
4 - RAPT Therapeutics, Inc. (0001673772) (Issuer)
SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT" or the "Company"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the first quarter ended March 31, 2025. "The year is off to a great start. We believe RPT904 has the potential to be a best-in-class option to treat patients with food allergy and are making good progress toward our planned initiation of a Phase 2b trial in the second half of 2025," said Brian Wong, President and CEO of RAPT. "We are
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E ("IgE"), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria ("CSU").
SOUTH SAN FRANCISCO, Calif., March 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following investor conferences in March: Leerink Global Healthcare Conference – Fireside chat on Tuesday, March 11, 2025 at 3:40 p.m. ET Barclays 27th Annual Global Healthcare Conference – Fireside chat on Wednesday, March 12, 2025 at 10:30 a.m. ET To access the live webcasts or subsequent archived recor
8-K - RAPT Therapeutics, Inc. (0001673772) (Filer)
8-K - RAPT Therapeutics, Inc. (0001673772) (Filer)
SCHEDULE 13G - RAPT Therapeutics, Inc. (0001673772) (Subject)
SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)
SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)
SC 13G/A - RAPT Therapeutics, Inc. (0001673772) (Subject)
SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Jessica Savage, M.D., M.H.S., as Vice President, Clinical Development to oversee the development of RPT904, a novel, half-life extended monoclonal antibody designed to bind free human immunoglobin E ("IgE"), a key driver of several allergic diseases. RAPT plans to pursue development of RPT904 initially in food allergy and chronic spontaneous urticaria ("CSU").
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced the appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations. "I am delighted to announce the addition of Nipun to the RAPT leadership team and welcome his wealth of experience in small molecule product development and commercial manufacturing," said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeu